GIANT BIOGENE (02367) spent approximately 14.03 million Hong Kong dollars to repurchase 400,000 shares on December 12th.
Giantbio (02367) announced that on December 12, 2025, it will spend approximately 14.0364 million Hong Kong dollars to repurchase 400,000 shares.
GIANT BIOGENE (02367) announced on December 12, 2025 that it will spend approximately HKD 14.0364 million to repurchase 400,000 shares of stock.
Related Articles
BUD APAC (01876) awards 29.38 million restricted share units.
ANHUI EXPRESSWAY (00995) plans to increase its investment in the traffic control information industry by 95 million RMB, increasing its shareholding ratio to 36.76%.
Medprin Regenerative Medical Technologies (301033.SZ) Shareholders Shenzhen Kaiying and Fengyan Fund plan to reduce their holdings by no more than 1.22%.
BUD APAC (01876) awards 29.38 million restricted share units.
ANHUI EXPRESSWAY (00995) plans to increase its investment in the traffic control information industry by 95 million RMB, increasing its shareholding ratio to 36.76%.
Medprin Regenerative Medical Technologies (301033.SZ) Shareholders Shenzhen Kaiying and Fengyan Fund plan to reduce their holdings by no more than 1.22%.
RECOMMEND
Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025
Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025
Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025
